MX2014014363A - Formulaciones estabilizadas que contienen anticuerpos anti-dll4. - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-dll4.Info
- Publication number
- MX2014014363A MX2014014363A MX2014014363A MX2014014363A MX2014014363A MX 2014014363 A MX2014014363 A MX 2014014363A MX 2014014363 A MX2014014363 A MX 2014014363A MX 2014014363 A MX2014014363 A MX 2014014363A MX 2014014363 A MX2014014363 A MX 2014014363A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations containing
- antibody
- dll4
- containing anti
- dll4 antibodies
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108700041286 delta Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 101150109170 dll4 gene Proteins 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo que se une específicamente a ligando tipo delta humano 4 (DII4). Las formulaciones pueden contener, además de un anticuerpo anti-Dl14, un amortiguador de fosfato, un cosolvente orgánico, un disacárido y una sal. Las formulaciones farmacéuticas de la presente invención conservan un grado sustancial de estabilidad del anticuerpo después de almacenamiento durante varios meses y después de ser sometidas a estrés térmico y otros estreses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653478P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/043516 WO2013181486A1 (en) | 2012-05-31 | 2013-05-31 | Stabilized formulations containing anti-dll4 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014363A true MX2014014363A (es) | 2015-02-05 |
| MX357146B MX357146B (es) | 2018-06-28 |
Family
ID=48670784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014363A MX357146B (es) | 2012-05-31 | 2013-05-31 | Formulaciones estabilizadas que contienen anticuerpos anti-dll4. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9675692B2 (es) |
| EP (1) | EP2854849B1 (es) |
| JP (1) | JP6144758B2 (es) |
| KR (1) | KR20150033615A (es) |
| CN (1) | CN104349791A (es) |
| AR (1) | AR092325A1 (es) |
| AU (1) | AU2013267301B2 (es) |
| BR (1) | BR112014028997A2 (es) |
| CA (1) | CA2872275C (es) |
| CL (1) | CL2014003237A1 (es) |
| CO (1) | CO7151478A2 (es) |
| DK (1) | DK2854849T3 (es) |
| EA (1) | EA029779B1 (es) |
| ES (1) | ES2668900T3 (es) |
| HK (1) | HK1207305A1 (es) |
| IL (1) | IL235468A0 (es) |
| LT (1) | LT2854849T (es) |
| MA (1) | MA37645B1 (es) |
| MX (1) | MX357146B (es) |
| NO (1) | NO2887943T3 (es) |
| NZ (1) | NZ702288A (es) |
| PH (1) | PH12014502429B1 (es) |
| PL (1) | PL2854849T3 (es) |
| PT (1) | PT2854849T (es) |
| SG (1) | SG11201407171XA (es) |
| SI (1) | SI2854849T1 (es) |
| SM (1) | SMT201800216T1 (es) |
| TW (1) | TWI609696B (es) |
| UY (1) | UY34842A (es) |
| WO (1) | WO2013181486A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CA3097058A1 (en) * | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| CA3185091A1 (en) * | 2020-07-08 | 2022-01-13 | Yuan Cheng | Stabilized formulations containing anti-ctla-4 antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| WO2008049897A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| EP3485908B1 (en) * | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| PL3721904T3 (pl) | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
| WO2011109298A2 (en) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| MX366337B (es) * | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-05-31 CA CA2872275A patent/CA2872275C/en active Active
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/en not_active Ceased
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 HK HK15108004.0A patent/HK1207305A1/xx unknown
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/en active Active
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Withdrawn
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 SM SM20180216T patent/SMT201800216T1/it unknown
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429B1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502429A1 (en) | Stabilized formulations containing anti-dll4 antibodies | |
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CY1121420T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| PH12013500225A1 (en) | Stabilized formulations containing anti-ngf antibodies | |
| MX2015000116A (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos. | |
| TN2009000382A1 (en) | Stable antibody formulations | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| BR112017002183A2 (pt) | conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero | |
| MY185802A (en) | Antibody formulation | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
| NZ702342A (en) | Pharmaceutical formulation | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| BR112014015605A2 (pt) | método de reconstituição para formulações de proteína seca de alta concentração | |
| CY1125584T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| TH154849A (th) | สูตรตำรับที่บรรจุแอนติบอดีต้าน-dll4 ที่ถูกเพิ่มความคงตัว | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |